Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ESRRA | P11474 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8252480 | 1.00 | HPGD (0.47) | HPGDPTPN1LMNAKMT2AESRRA | |
| SCHEMBL4935145 | 1.00 | HPGD (0.47) | HPGDPTPN1LMNAKMT2AESRRA | |
| SCHEMBL4924394 | 0.92 | ADAMTS5 (0.46) | LMNAKMT2APDE4BCISD1 | |
| SCHEMBL4924380 | 0.92 | ADAMTS5 (0.46) | LMNAKMT2APDE4BCISD1 | |
| SCHEMBL8252684 | 0.90 | HPGD (0.49) | HPGD | |
| SCHEMBL4933204 | 0.90 | HPGD (0.49) | HPGD | |
| SCHEMBL4933200 | 0.90 | HPGD (0.49) | HPGD | |
| SCHEMBL4929577 | 0.89 | HPGD (0.49) | HPGDPTPN1ESRRAPIM1PIM2 | |
| SCHEMBL4936377 | 0.89 | HPGD (0.49) | HPGDPTPN1ESRRAPIM1PIM2 | |
| SCHEMBL4928339 | 0.89 | HPGD (0.53) | HPGDPTPN1AKR1B1PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080267888-A1 | Heterocyclic Derivatives | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2008-10-30 | — | — | US | claimed |
| WO-2006126074-A2 | HETEROCYCLIC DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2006-11-30 | — | — | WO | claimed |
| US-20080267888-A1 | Heterocyclic Derivatives | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267888-A1 | Heterocyclic Derivatives | CYP11B2, MAPT, UGT1A1 | HPGD 593/4885PTPN1 3665/4885LMNA 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.